<DOC>
	<DOCNO>NCT01268787</DOCNO>
	<brief_summary>This study aim evaluate safety , reactogenicity immunogenicity EV71 vaccine 0.25ml 0.5ml dose health volunteer</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity EV71 Vaccine</brief_title>
	<detailed_description>This phase I , prospective , randomize , open-label , two-center study . A total 60 healthy volunteer screen baseline characteristic inclusion/exclusion criterion provide write informed consent . Eligible subject recruit equally randomize either receive 2 dos EV71 vaccine 0.25ml 0.5ml . All subject follow till Day 210 .</detailed_description>
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject free obvious health problem Able willing comply study procedure adn give write informed consent Female pregnant/lactating plan pregnant Body mass index ( BMI ) &gt; 35 Oral temperature &gt; 37.5 Celsius time plan vaccination Subject abnormal laboratory result screen With history herpangina , handfootmouth disease , acute hemorrhagic conjunctivitis acute gastrointestinal illness associate enterovirus infection past 3 month Has diagnose neurological , pulmonary , cardiovascular , hematological , hepatic renal disorder With history hypersensitivity vaccine allergic disease Use investigational/nonregistered product within 30 day prior vaccination Use immunoglobulins blood product within 3 month prior vaccination Chronic administration immunosuppressant immunomodulators within 5 month prior vaccination</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>